The development, validation and application of a 32P-postlabelling assay to quantify O6-methylguanine in human DNA.
Affiliation
Department of Carcinogenesis, Paterson Institute for Cancer Research, Manchester, UK.Issue Date
1995-07
Metadata
Show full item recordAbstract
In this study, a combined immunoaffinity purification/32P-postlabelling procedure has been used to quantify O6-methyldeoxyguanosine-3'-monophosphate (O6-MedGp) in human DNA. DNA digests are subjected to a two-stage immunopurification in which the acetone-eluted fraction from the first stage is reapplied to a second immunocolumn, and the O6-MedGp specifically eluted using O6-methylguanosine (O6-MerG). O6-MedGp is then 32P-postlabelled in the presence of deoxyinosine-3'-monophosphate (dIp) as internal standard, separated by two-dimensional TLC and levels of the adduct quantified using storage phosphor technology. The recovery of O6-MedGp at levels between 0.4 and 500 fmol was 61%. Analysis of human DNA samples indicated that < 1 fmol O6-methyldeoxy-guanosine-5'-monophosphate (O6-MepdG) could be detected with a high degree of precision (coefficient of variation < 12%) during a 2 h exposure to a storage phosphor screen. The assay was then applied to 25 human samples from three separate populations, one of which was exposed to methylating agent chemotherapy, for which O6-methyl-deoxyguanosine (O6-MedG) levels had already been quantified by HPLC/radioimmunoassay. The results indicated a high degree of correlation between the two assays (r = 0.99). O6-MedGp was detected in all the samples analysed with levels ranging from 0.026 to 23.2 mumol O6-MedGp/mol dG. The minimum amount of O6-MepdG detected was 0.2 fmol. As there was no detectable signal in the area to which O6-MepdG maps in negative control samples, a detection limit based upon the signal/noise ratio was impossible to quantify. However the limit of detection of the storage phosphor technology itself was estimated by quantifying a visually identifiable compound, which mapped to the same region. The amount of this compound was determined to be 32 +/- 27 amol (n = 5). If a similar amount of O6-MepdG was detected from 50 micrograms of DNA, and assuming that the labelling efficiency and recovery was similar to that found in this study, then this would correspond to an adduct level of approximately 3 nmol O6-MedGp/mol dG.Citation
The development, validation and application of a 32P-postlabelling assay to quantify O6-methylguanine in human DNA. 1995, 16 (7):1665-9 CarcinogenesisJournal
CarcinogenesisDOI
10.1093/carcin/16.7.1665PubMed ID
7614705Type
ArticleLanguage
enISSN
0143-3334ae974a485f413a2113503eed53cd6c53
10.1093/carcin/16.7.1665
Scopus Count
Collections
Related articles
- Optimization of 32P-postlabelling assays for the quantitation of O6-methyl and N7-methyldeoxyguanosine-3'-monophosphates in human DNA.
- Authors: Haque K, Cooper DP, Povey AC
- Issue date: 1994 Nov
- Accurate and sensitive quantitation of N7-methyldeoxyguanosine-3'-monophosphate by 32P-postlabeling and storage-phosphor imaging.
- Authors: Haque K, Cooper DP, van Delft JH, Lee SM, Povey AC
- Issue date: 1997 Jun
- Immunoaffinity purification combined with 32P-postlabelling for the detection of O6-methylguanine in DNA from human tissues.
- Authors: Cooper DP, Griffin KA, Povey AC
- Issue date: 1992 Mar
- Combined micropreparative techniques with synchronous fluorescence spectroscopy or 32P-postlabelling assay for carcinogen-DNA adduct determination.
- Authors: Shields PG, Kato S, Bowman ED, Petruzzelli S, Cooper DP, Povey AC, Weston A
- Issue date: 1993
- Associations between smoking, GST genotypes and N7-methylguanine levels in DNA extracted from bronchial lavage cells.
- Authors: Lewis SJ, Cherry NM, Niven RM, Barber PV, Povey AC
- Issue date: 2004 Apr 11